These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18020402

  • 1. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 2. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Jan; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.
    Bioconjug Chem; 2006 Jan; 17(1):179-88. PubMed ID: 16417267
    [Abstract] [Full Text] [Related]

  • 5. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
    Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y.
    J Med Chem; 2004 Sep 23; 47(20):4897-904. PubMed ID: 15369394
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM, Chan LJ, Ryan GM, Porter CJ, Kaminskas LM.
    J Pharm Sci; 2015 Apr 23; 104(4):1421-30. PubMed ID: 25631360
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T, Takimoto A, Notsu Y, Yoshida H, Ito T, Nagatome H, Ohno M, Kobayashi Y, Yoshioka T, Inagaki K, Yagi S, Hoffman RM, Esaki N.
    Cancer Res; 2006 Mar 01; 66(5):2807-14. PubMed ID: 16510603
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK, Qadir MA, Mahmood N, Ahmed M.
    Protein Pept Lett; 2020 Mar 01; 27(3):219-224. PubMed ID: 31612813
    [Abstract] [Full Text] [Related]

  • 13. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS, Lee KC.
    Bioconjug Chem; 2007 Mar 01; 18(2):500-6. PubMed ID: 17243755
    [Abstract] [Full Text] [Related]

  • 14. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.
    J Interferon Cytokine Res; 2013 Dec 01; 33(12):769-77. PubMed ID: 23962003
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
    Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M.
    Proc Natl Acad Sci U S A; 2001 Jan 30; 98(3):1212-7. PubMed ID: 11158619
    [Abstract] [Full Text] [Related]

  • 17. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
    Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S.
    Bioconjug Chem; 2007 Jan 30; 18(1):61-76. PubMed ID: 17226958
    [Abstract] [Full Text] [Related]

  • 18. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.
    Int J Pharm; 2006 Feb 17; 309(1-2):87-93. PubMed ID: 16406701
    [Abstract] [Full Text] [Related]

  • 19. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
    Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y.
    Clin Cancer Res; 2004 Dec 15; 10(24):8293-300. PubMed ID: 15623605
    [Abstract] [Full Text] [Related]

  • 20. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY.
    Bioconjug Chem; 2007 Dec 15; 18(1):41-9. PubMed ID: 17226956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.